TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.43
-0.10% today
Updated 2026-04-29
Market cap
$3.53B
P/E ratio
—
P/S ratio
4.40x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $19
Volume
0.3M
Telix Pharmaceuticals Limited (TLX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-524756.00 | $-1.21M | $-1.88M | $-3.51M | $-1.07M | $-6.03M | $-20.75M | $-23.33M | $1.96M | $-59.33M | $-63.97M | $23.88M | $43.03M | $-25.93M |
| Capital expenditures | $63010.00 | $199402.00 | $96553.00 | $239990.00 | $2.83M | $5642.00 | $198730.00 | $403000.00 | $248000.00 | $1.34M | $7.04M | $9.68M | $14.32M | $56.86M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | $109020.00 | $712000.00 | $1.27M | $2.35M | $1.32M | $8.11M | $8.79M | $19.66M | — |
| Free cash flow | $-587766.00 | $-1.40M | $-1.98M | $-3.75M | $-3.90M | $-6.04M | $-20.95M | $-23.74M | $1.71M | $-60.67M | $-71.01M | $14.21M | $28.71M | $-82.80M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $54.79M | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — |